Remoxipride

IUPAC: (S )-3- bromo-N -(1- ethyl-2- pyrrolidinylmethyl ) - 2,6- dimethoxybenzamide

  • C16H23BrN2O3 ( remoxipride )
  • C16H23BrN2O3 ( · remoxipride hydrochloride monohydrate · )
  • 80125-14-0 ( remoxipride )
  • 117591-79-4 ( · remoxipride hydrochloride monohydrate · )

N05AL04

Atypical Antipsychotics

  • 371.27 g · mol -1 ( remoxipride )
  • 425.75 g · mol -1 ( · remoxipride hydrochloride monohydrate · )

173 ° C

Template: Infobox chemical / molecular formula search available

Remoxipride is an atypical antipsychotic drug, which was used in the early 1990s in psychiatry. From the chemical structure, it is a benzamide.

History

Remoxipride was allowed from 1991 until the end of 1993 for the treatment of schizophrenic psychoses. The trade name of the original preparation was ROXIAM ®; the daily dose was 150-450 mg ( max. 600 mg) in the form of capsules for oral use, even an injection solution was available.

Withdrawal

The end of 1993 ROXIAM was taken by the manufacturer of the world market, as the revocation of regulatory approval for remoxipride threatened. Cause fatal cases were cases of aplastic anemia, damage to the blood cells in the bone marrow, which were caused by remoxipride ( risk 1 to 2000). The benefit-risk ratio of this low potency neuroleptic was therefore clearly negative.

CAS registry number PubChem Anatomical Therapeutic Chemical Classification System DrugBank Psychosis
677637
de